Journal
GENE THERAPY
Volume -, Issue -, Pages -Publisher
SPRINGERNATURE
DOI: 10.1038/s41434-023-00406-0
Keywords
-
Ask authors/readers for more resources
Spinal muscular atrophy (SMA) is a neuromuscular disease caused by mutations in the survival motor neuron (SMN) 1 gene. A novel codon-optimized hSMN1 transgene was developed and lentiviral vectors with different promoters were tested for optimal expression. The integration-deficient lentiviral vectors showed high expression of the optimized transgene and are considered safer. Neonatal delivery of the optimized transgene using adeno-associated viral vectors resulted in a significant increase in SMN protein levels in SMA mouse models.
Spinal muscular atrophy (SMA) is a neuromuscular disease particularly characterised by degeneration of ventral motor neurons. Survival motor neuron (SMN) 1 gene mutations cause SMA, and gene addition strategies to replace the faulty SMN1 copy are a therapeutic option. We have developed a novel, codon-optimised hSMN1 transgene and produced integration-proficient and integration-deficient lentiviral vectors with cytomegalovirus (CMV), human synapsin (hSYN) or human phosphoglycerate kinase (hPGK) promoters to determine the optimal expression cassette configuration. Integrating, CMV-driven and codon-optimised hSMN1 lentiviral vectors resulted in the highest production of functional SMN protein in vitro. Integration-deficient lentiviral vectors also led to significant expression of the optimised transgene and are expected to be safer than integrating vectors. Lentiviral delivery in culture led to activation of the DNA damage response, in particular elevating levels of phosphorylated ataxia telangiectasia mutated (pATM) and gamma H2AX, but the optimised hSMN1 transgene showed some protective effects. Neonatal delivery of adeno-associated viral vector (AAV9) vector encoding the optimised transgene to the Smn(2B/-) mouse model of SMA resulted in a significant increase of SMN protein levels in liver and spinal cord. This work shows the potential of a novel codon-optimised hSMN1 transgene as a therapeutic strategy for SMA.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available